LRMR Larimar Therapeutics Inc
Price (delayed)
$7.24
Market cap
$461.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.11
Enterprise value
$433.9M
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical
Highlights
LRMR's equity has surged by 112% year-on-year but it is down by 8% since the previous quarter
The company's net income has shrunk by 79% YoY and by 29% QoQ
The EPS has decreased by 46% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of LRMR
Market
Valuations
Earnings
Shares outstanding
63.81M
Market cap
$461.96M
Enterprise value
$433.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$58.34M
EBITDA
-$58.13M
Free cash flow
-$43.38M
Per share
Balance sheet
Liquidity
EPS
-$1.11
Free cash flow per share
-$0.68
Book value per share
$3.31
Revenue per share
$0
TBVPS
$3.72
Total assets
$237.16M
Total liabilities
$25.76M
Debt
$5.6M
Equity
$211.4M
Working capital
$209.98M
Debt to equity
0.03
Current ratio
10.93
Quick ratio
10.75
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.1%
Return on equity
-37.8%
Return on invested capital
-52.6%
Return on capital employed
-27%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LRMR stock price
How has the Larimar Therapeutics stock price performed over time
Intraday
-3.21%
1 week
-18.65%
1 month
-4.99%
1 year
80.55%
YTD
59.12%
QTD
-0.14%
Financial performance
How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.83M
Net income
-$58.34M
Gross margin
N/A
Net margin
N/A
Larimar Therapeutics's operating income has shrunk by 82% YoY and by 29% QoQ
The company's net income has shrunk by 79% YoY and by 29% QoQ
Growth
What is Larimar Therapeutics's growth rate over time
Valuation
What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
2.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 46% YoY and by 16% from the previous quarter
LRMR's equity has surged by 112% year-on-year but it is down by 8% since the previous quarter
LRMR's P/B is 26% above its 5-year quarterly average of 1.8 and 8% above its last 4 quarters average of 2.1
Efficiency
How efficient is Larimar Therapeutics business performance
The ROIC has grown by 39% YoY and by 21% from the previous quarter
Larimar Therapeutics's ROA has decreased by 28% YoY and by 6% from the previous quarter
LRMR's ROE is down by 26% year-on-year and by 6% since the previous quarter
Dividends
What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LRMR.
Financial health
How did Larimar Therapeutics financials performed over time
LRMR's total liabilities has surged by 119% year-on-year and by 48% since the previous quarter
The total assets has soared by 112% YoY but it is down by 4.4% QoQ
The debt is 97% less than the equity
LRMR's equity has surged by 112% year-on-year but it is down by 8% since the previous quarter
LRMR's debt to equity has soared by 50% from the previous quarter but it is down by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.